Fake Medicines in Africa: Why QR Authentication Is the Only Scalable Solution

Of all counterfeit categories, falsified medicine is the one where the cost is measured in lives rather than revenue. The WHO estimates that roughly one in ten medical products circulating in low- and middle-income countries is substandard or falsified, and reports from Sub-Saharan Africa are heavily over-represented in its global surveillance data.

The harm is not confined to the patient who takes the fake. Sub-therapeutic antimalarials and antibiotics — products containing some active ingredient, but too little — are an efficient way to breed resistant pathogens. A falsified antibiotic can therefore injure people who never encountered it, years later, by making a whole class of drugs less effective.

Why pharmaceutical supply chains are hard to secure here

The high-income model of pharmaceutical security assumes conditions that frequently do not hold in African markets.

Dispensing is decentralised

In much of Europe and North America, medicines reach patients through a relatively small number of licensed pharmacy chains with integrated inventory systems. Across much of Africa, dispensing runs through tens of thousands of independent pharmacies, clinics, drug shops, and informal vendors. There is no central system to push a recall through and no consolidated inventory to audit.

The chain has many hands

Product may pass through an importer, a national distributor, a regional wholesaler, a sub-wholesaler, and a retailer. Each transfer is a point where counterfeit stock can be introduced into an otherwise legitimate flow. Falsified product frequently enters mid-chain, which means the retailer selling it is often an unwitting participant rather than a conspirator.

Verification infrastructure is unevenly distributed

Systems that require every dispensing point to operate a scanner terminal and a reliable data connection work well in a chain pharmacy in a capital city and not at all in a rural drug shop. Any solution whose coverage stops where the infrastructure stops will miss precisely the markets where falsification is most common.

Where conventional track-and-trace runs out

Regulatory serialisation frameworks were a genuine advance, and they have measurably reduced falsification in the markets that mandated them. But their architecture carries assumptions that limit them here.

• ●They are custody systems, not consumer systems. They verify product as it moves between licensed entities. If falsified stock enters below that layer — at an unlicensed vendor, or at the counter — the framework never sees it.
• ●They require universal participation to work. Serialisation that covers 60% of dispensing points leaves an obvious 40% for counterfeit product to flow through.
• ●They are jurisdictional. Requirements differ by country, while counterfeit supply chains cross borders freely.
• ●They verify the transaction, not the physical unit. Most such systems check that a serial exists and is in the expected state — which does not detect a valid serial that has been copied onto ten thousand fakes.

Why the patient has to be the verifier

The only participant present at every single dispensing event, in every market, formal or informal, is the person receiving the medicine. They are also the participant with the strongest incentive to check. Any system that scales to the whole market has to put verification in their hands.

That constraint dictates most of the design. It must run on an ordinary phone with no app install, because asking a patient to download software before taking their medication is a requirement that will simply not be met. It must work on a slow connection and a low-end handset. It must return a result in seconds and state it in unambiguous language rather than a technical code. And it must be free to the patient, forever, with no cap on scans.

What verification needs to tell the patient

A bare "valid" or "invalid" is not enough for a medical product. A useful result confirms the specifics the patient can check against what they are holding:

• ●The product name and strength — so a patient can catch a code lifted from a different SKU.
• ●The batch or lot number, matching the physical pack, which also makes recall communication possible.
• ●Whether this unit's code has been verified before, and how often — the primary signal of a copied label.
• ●Whether the product is being scanned in the market it was manufactured for.
• ●A clear, calm instruction about what to do if something is wrong, including how to report it.

That last point deserves emphasis. A verification result that alarms a patient into abandoning genuine treatment causes harm of its own. Wording matters: the goal is to prompt a check with the pharmacist, not to panic someone out of taking necessary medication.

Turning scans into enforcement

The consumer-verification layer produces something the custody layer never could: a live map of where falsified product is actually reaching patients. Failed verifications and duplicate-code detections cluster geographically, and those clusters point at the entry point into the distribution chain.

This is the evidence regulators and law enforcement need and rarely have. Instead of acting on a complaint weeks after the fact, a national medicines authority can be shown a cluster of duplicate-code detections concentrated in a specific area over a specific fortnight. That is actionable.

A realistic starting point

Manufacturers frequently stall on scope, waiting for a plan that covers every product in every market. A narrower start produces results faster:

1. 1Begin with the products counterfeiters actually target — high-volume, high-margin, and health-critical. Antimalarials, antibiotics, and analgesics are the usual candidates.
2. 2Take one production run in one market and carry it end to end, rather than piloting shallowly across many.
3. 3Print the verification prompt on the secondary pack where a patient will see it, with instructions in the languages actually spoken in that market.
4. 4Brief pharmacists and dispensers first. They are the ones patients will ask, and an informed dispenser converts a verification into a genuine safety intervention.
5. 5Collect several weeks of baseline scan data before drawing conclusions. Early anomalies are often distribution quirks rather than counterfeiting; the pattern needs time to separate.

Falsified medicine persists in African markets because verification has been harder than falsification. Putting a cryptographic check into the hands of every patient with a phone reverses that, and it does so without waiting for infrastructure that does not yet exist.